secwatch.observer — SEC 8-K summary
======================================

Issuer:     Autonomix Medical, Inc. (AMIX)
CIK:        0001617867
Form:       8-K
Filed at:   2025-02-13T23:59:59+00:00
Accession:  0001437749-25-003673
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Autonomix Medical reports Q3 FY2025 net loss of $2.7M, cash $11.8M; PoC trial data on track for 1H2025
--------------------------------------------------------------------------------

- Net loss of $2.7M for Q3 ended Dec 31, 2024 vs $3.1M a year ago; nine-month net loss $8.2M vs $10.0M.
- Cash position $11.8M as of Dec 31, 2024; raised $10M in underwritten public offering during the quarter.
- Topline proof-of-concept trial data for pancreatic cancer pain expected in 1H2025; US clinical trials targeted for 2H2025.
- Achieved design lock for RF ablation catheter after successful animal testing; expanded IP with new U.S. patent grant.
- Targeting De Novo submission in 2026 and potential FDA clearance for pancreatic cancer pain in 2027.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1617867/000143774925003673/0001437749-25-003673-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1617867/000143774925003673/amix20250210_8k.htm
  HTML page:      https://secwatch.observer/filing/0001437749-25-003673

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer